No Data
No Data
Myriad Genetics Shares Fall Despite Partnership With Jscreen
Myriad Genetics and Jscreen Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible With Electronic Medical Record Integration
Myriad Genetics (NASDAQ:MYGN) Shareholders Are Still up 61% Over 1 Year Despite Pulling Back 7.9% in the Past Week
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $32
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $34
Jaguar8 : Yes it’s quite disappointing that people don’t realize the importance of this.
Trytosaveabit OP Jaguar8 : Yup! I have a volume and price move alerts set! Hehehe
Jaguar8 Trytosaveabit OP : What volume do you usually set like 1M?
Trytosaveabit OP Jaguar8 : 300K in 3 minutes
Jaguar8 Trytosaveabit OP : Wow that is fast volume
View more comments...